A detailed history of Ifg Advisory, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ifg Advisory, LLC holds 2,181 shares of VRTX stock, worth $1.03 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
2,181
Holding current value
$1.03 Million
% of portfolio
0.07%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$392.81 - $485.53 $856,718 - $1.06 Million
2,181 New
2,181 $1.02 Million
Q4 2023

Jan 17, 2024

BUY
$343.0 - $410.68 $4,802 - $5,749
14 Added 0.61%
2,319 $943,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $779,504 - $835,470
2,305 New
2,305 $801,000
Q1 2023

Apr 26, 2023

SELL
$283.23 - $323.1 $5,664 - $6,462
-20 Reduced 0.85%
2,342 $737,000
Q4 2022

Jan 31, 2023

BUY
$285.76 - $321.48 $8,287 - $9,322
29 Added 1.24%
2,362 $682,000
Q3 2022

Oct 28, 2022

BUY
$273.83 - $305.53 $638,845 - $712,801
2,333 New
2,333 $675,000
Q3 2019

Nov 06, 2019

SELL
$166.23 - $187.09 $376,344 - $423,571
-2,264 Closed
0 $0
Q2 2019

Aug 06, 2019

BUY
$164.61 - $190.37 $7,736 - $8,947
47 Added 2.12%
2,264 $415,000
Q1 2019

May 08, 2019

SELL
$163.73 - $194.7 $25,869 - $30,762
-158 Reduced 6.65%
2,217 $407,000
Q4 2018

Feb 07, 2019

BUY
$151.91 - $192.21 $303 - $384
2 Added 0.08%
2,375 $393,000
Q3 2018

Nov 05, 2018

SELL
$167.73 - $192.74 $2,012 - $2,312
-12 Reduced 0.5%
2,373 $457,000
Q2 2018

Aug 02, 2018

BUY
$145.72 - $169.96 $20,692 - $24,134
142 Added 6.33%
2,385 $405,000
Q1 2018

Apr 26, 2018

SELL
$151.6 - $177.13 $758 - $885
-5 Reduced 0.22%
2,243 $0
Q4 2017

Feb 01, 2018

SELL
$137.28 - $155.55 $5.08 Million - $5.75 Million
-36,988 Reduced 94.27%
2,248 $336,000
Q4 2017

Jan 29, 2018

BUY
$137.28 - $155.55 $5.39 Million - $6.1 Million
39,236
39,236 $353,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ifg Advisory, LLC Portfolio

Follow Ifg Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifg Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ifg Advisory, LLC with notifications on news.